Irena Angelova Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irena Angelova Fischer has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Assen Dourmishev
1 shared publicationJana Kazandjieva
1 shared publicationNikolai Tsankov
1 shared publication- Snejina Vassileva
Department of Dermatology and Venereology, Medical University - Sofia, Sofia, Bulgaria
1 shared publication
Latest Publications
- 1 September 2005
- Vol. 14 (3) , 115-9
Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Leukotrienes are potent proinflammatory mediators derived from of arachidonic acid through the 5- lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a rationale for the use of pharmacological agents to antagonize their effects in the treatment of atopic dermatitis. We report 2 cases of severe atopic dermatitis successfully treated with montelukast as a single therapeutic agent in a daily dose of 10 mg for 8 weeks when corticosteroid treatment was contraindicated or failed to control the disease. Our observations suggest that montelukast may be used as an alternative steroid sparing medication for severe atopic dermatitis, especially in patients with associated asthma and rhinitis.
- 1 September 2005
- Vol. 14 (3) , 115-9
Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Leukotrienes are potent proinflammatory mediators derived from of arachidonic acid through the 5- lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a rationale for the use of pharmacological agents to antagonize their effects in the treatment of atopic dermatitis. We report 2 cases of severe atopic dermatitis successfully treated with montelukast as a single therapeutic agent in a daily dose of 10 mg for 8 weeks when corticosteroid treatment was contraindicated or failed to control the disease. Our observations suggest that montelukast may be used as an alternative steroid sparing medication for severe atopic dermatitis, especially in patients with associated asthma and rhinitis.
- 1 June 2005
- Vol. 14 (2) , 61-7
Kindler syndrome: a case report and proposal for clinical diagnostic criteria.
Kindler syndrome is a rare hereditary disorder characterized by acral blister formation in infancy and childhood, progressive poikiloderma, cutaneous atrophy and increased photosensitivity. Since it was first described in 1954, less than 100 cases have been reported worldwide. Recently it has been reported that Kindler syndrome is the first genodermatosis caused by a defect in the actin-extracellular matrix linkage, and the gene was mapped to chromosome 20p12.3. The clinical features of the syndrome have been annotated by different authors but the definite of criteria to confirm the diagnosis have not yet been generally accepted. We report a case of Kindler syndrome that presents a full spectrum of clinical manifestations, and we propose a set of clinical criteria for diagnosis.
- 1 June 2005
- Vol. 14 (2) , 61-7
Kindler syndrome: a case report and proposal for clinical diagnostic criteria.
Kindler syndrome is a rare hereditary disorder characterized by acral blister formation in infancy and childhood, progressive poikiloderma, cutaneous atrophy and increased photosensitivity. Since it was first described in 1954, less than 100 cases have been reported worldwide. Recently it has been reported that Kindler syndrome is the first genodermatosis caused by a defect in the actin-extracellular matrix linkage, and the gene was mapped to chromosome 20p12.3. The clinical features of the syndrome have been annotated by different authors but the definite of criteria to confirm the diagnosis have not yet been generally accepted. We report a case of Kindler syndrome that presents a full spectrum of clinical manifestations, and we propose a set of clinical criteria for diagnosis.